Oxolamine

Oxolamine

SCHEMBL893333

CCN(CC)CCc1nc(-c2ccccc2)no1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 1.00
HRH3 Q9Y5N1 1/20 1.00
CYP1A2 P05177 2/20 0.72
CYP2D6 P10635 1/20 0.72
HIF1A Q16665 1/20 0.72
L3MBTL1 Q9Y468 6/20 0.60
RAB9A P51151 6/20 0.60
NPC1 O15118 5/20 0.60
CYP2C19 P33261 1/20 0.60
NOTUM Q6P988 1/20 0.55
ALDH1A1 P00352 3/20 0.54
HTT P42858 1/20 0.53
TDP1 Q9NUW8 3/20 0.51
ATM Q13315 1/20 0.51
MAPK1 P28482 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TSHR P16473 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxolamine SCHEMBL1652318 0.98 HTR1A (0.97) HTR1AHRH3CYP1A2CYP2D6HIF1A
Oxolamine SCHEMBL4414451 0.86 CYP1A2 (0.78) HTR1AHRH3CYP1A2CYP2D6HIF1A
Oxolamine SCHEMBL3498928 0.85 CYP1A2 (1.00) HTR1AHRH3CYP1A2CYP2D6HIF1A
SCHEMBL7947228 0.84 HTR1A (0.73) HTR1AHRH3CYP1A2CYP2D6HIF1A
SCHEMBL29376403 0.83 HTR1A (0.71) HTR1AHRH3CYP1A2CYP2D6HIF1A
SCHEMBL14288613 0.82 RAB9A (0.70) HTR1AHRH3CYP1A2L3MBTL1RAB9A
SCHEMBL7961634 0.79 HTR1A (0.65) HTR1AHRH3CYP1A2L3MBTL1RAB9A
SCHEMBL91541 0.79 NOTUM (0.68) HTR1AHRH3CYP1A2L3MBTL1RAB9A
Dimethylamine SCHEMBL7961636 0.78 HTR1A (0.64) HTR1AHRH3CYP1A2L3MBTL1RAB9A
SCHEMBL7961648 0.78 HTR1A (0.63) HTR1AHRH3CYP1A2L3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255781-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-08-14 US claimed
US-12296043-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2025-05-13 US claimed
CN-119948030-A Protease/enzyme cleavable linker-payload and protein conjugates 苏特罗生物制药公司 2025-05-06 CN claimed
CN-119855614-A Beta-glucuronide linker-payload, protein conjugates thereof and methods thereof 苏特罗生物制药公司 2025-04-18 CN claimed
EP-4510999-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS Bristol-Myers Squibb Company (US) 2025-02-26 EP claimed
CN-119212681-A Method for preparing 3-D printed pharmaceutical products 百时美施贵宝公司 2024-12-27 CN claimed
US-12102653-B2 Ligand regulated protein-protein interaction system ST. ANNA KINDERKREBSFORSCHUNG (AT) 2024-10-01 US claimed
CN-118206634-A Ligand-regulated protein-protein interaction system 圣安娜儿童癌症研究中心 2024-06-18 CN claimed
US-20240165020-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-05-23 US claimed
EP-4360653-A2 LIQUISOFT CAPSULES Patheon Softgels Inc. (US) 2024-05-01 EP claimed
EP-1651184-A1 FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS Warner-Lambert Company LLC (US) 2006-05-03 EP claimed
CN-1750809-A Fast dissolving orally consumable films containing pharmaceutically active agents WARNER LAMBERT CO (US) 2006-03-22 CN claimed
WO-2004096174-A1 FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-11 WO claimed
US-6699841-B2 ADDING TRISUBSTITUTED SALT OF GLYCYRRHIZIC ACID TO AQUEOUS SOLTUION OF FIRST PHYSIOLOGICALLY ACCEPTABLE COMPOUND OF AN ACIDIC NATURE, AND SECOND PHYSIOLOGICALLY ACCEPTABLE COMPOUND OF A BASIC NATURE BAIOCCHI LEANDRO (IT) 2004-03-02 US claimed
US-20030206942-A1 Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent MCNEIL-PPC, INC 2003-11-06 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-20020193322-A1 Method of preparing physiologically acceptable aqueous solutions, and solutions thus obtained BAIOCCHI LEANDRO (IT) 2002-12-19 US claimed
EP-1226831-A1 Aqueous pharmaceutical solutions with trisubstituted glycyrrhizic acid salts Baiocchi, Leandro (IT) 2002-07-31 EP claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed